华润双鹤：子公司盐酸替罗非班氯化钠注射液获得药品注册证书

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., has received the drug registration certificate for Sodium Chloride Injection of Tirofiban Hydrochloride from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] Summary by Category - Regulatory Approval - The company has obtained the drug registration certificate for Sodium Chloride Injection of Tirofiban Hydrochloride, indicating compliance with national regulations [1] - Research and Development Investment - The total R&D investment for this drug has reached 3.7558 million RMB (approximately 0.37558 million) as of the date of the announcement [1]